StockTipsArenaBeta

BUY Dr. Lal Path Labs Ltd. — Deven Mehata, IDBI Capital Markets and Securities

BUYDr. Lal Path Labs Ltd.
Dr. Lal Path Labs share price target & all analyst calls

byDeven Mehata, IDBI Capital Markets and SecuritiesHorizon: NA (inferred Swing (≤2wk))5 Oct 2026via NDTV Profit (Live)

Entry₹2,005.9Inferred
Target₹2,165
Total upside +7.93%
Stop loss₹1,925-4.03% risk
CMP₹1,971.3Just now
Active-1.72%+9.83%upside left 11d left
Follow Deven Mehata for new calls(13% target hit, 67 closed calls)Get alertsWatch LALPATHLAB for new buy/sell callsGet alertsSee 2 other Swing calls on LALPATHLABSee 68 other Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 5 Oct, 3:45 pm IST
7 supporting0 opposing
Supports the BUY call (7)

MACD above its signal line — bullish momentum

Technicals · macd·5 Oct · today

2 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · same horizon·5 Oct · today

3 advisors have active short-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · adjacent horizon·1 Oct · 4d ago

Dr. Lal PathLabs Ltd announces the completion of its acquisition of an 80% stake in Sunshine Healthcare Limited, Ghana, through its wholly-owned subsidiary DLPL Dubai. Sunshine Healthcare Limited is n

BSE · Company Update·26 Sept · 1w ago

(opens in new tab)

Dr. Lal Path Labs Ltd. approved the acquisition of 70% stake in SN Genelab Private Limited for up to INR 168 Crores plus performance linked earn out. SN Genelab will become a subsidiary.

NSE · Outcome of Board Meeting·24 Sept · 1w ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Dr. Lal Path Labs

All analyst calls on Dr. Lal Path Labs

More from Deven Mehata, IDBI Capital Markets and Securities

Every call and its outcome